Pharma News

Piramal Enterprises considers potential acquisition of Kentucky based Specialty Pharmaceutical CDMO, Coldstream Laborator ies Inc

  • Posted on: 16 January 2015
  • By: PharmaTutor News

Piramal Enterprises Limited today announced that it is in final stages of discussion with the University of Kentucky for the potential acquisition of Coldstream Laboratories Inc. (‘Coldstream’) for a total consideration of USD 30.65 million.

Bristol-Myers Squibb and California Institute for Biomedical Research (Calibr) sign worldwide research collaboration and license agreement focused on new treatment approaches for Fibrotic Diseases

  • Posted on: 6 January 2015
  • By: PharmaTutor News

Bristol-Myers Squibb (BMS) Company and the California Institute for Biomedical Research (Calibr) entered into a worldwide research collaboration to develop novel small molecule anti-fibrotic therapies, and an exclusive license agreement that allows BMS to develop, manufacture and commercialize Calibr’s preclinical compounds resulting from the collaboration.

Quintiles Named Best Contract Research Organization at SCRIP Awards for Third Consecutive Year

  • Posted on: 6 January 2015
  • By: PharmaTutor News

Quintiles today announced that the company was awarded “Best Contract Research Organization” at the annual SCRIP Awards for the third year in-a-row. This is the company’s fourth award received in this category in the last five years. The SCRIP Awards acknowledge excellence in the biopharmaceutical industry, based on judging by an independent panel of 12 life sciences experts.

Stem Cell Transplants may halt progression of Multiple Sclerosis

  • Posted on: 2 January 2015
  • By: PharmaTutor News

Three-year outcomes from an ongoing clinical trial suggest that high-dose immunosuppressive therapy followed by transplantation of a person's own blood-forming stem cells may induce sustained remission in some people with relapsing-remitting multiple sclerosis (RRMS). RRMS is the most common form of MS, a progressive autoimmune disease in which the immune system attacks the brain and spinal cord. The trial is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and conducted by the NIAID-funded Immune Tolerance Network (ITN).

Hazardous Waste Treatment Proves More Effective than Disposal, Observes Frost & Sullivan

  • Posted on: 31 December 2014
  • By: admin

The skewed ratio of hazardous waste generated daily to innovations in hazardous waste management, points to a large unmet need for novel hazardous waste management technologies and processes. Apart from the rising volumes of hazardous waste, technology development in this space will also get a huge boost from the treaties signed by various countries for stopping transboundary waste shipping and public opposition to landfills.

World's first regulatory approval of Novartis' Cosentyx(TM) in Japan for both psoriasis and psoriatic arthritis

  • Posted on: 29 December 2014
  • By: PharmaTutor News

Novartis announced today that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Cosentyx(TM) (secukinumab, formerly known as AIN457), for the treatment of both psoriasis vulgaris and psoriatic arthritis (PsA) in adults who are not adequately responding to systemic therapies (except for biologics). This approval marks the first country approval for Cosentyx in the world and makes it the first interleukin-17A (IL-17A) inhibitor to receive regulatory approval in either of these indications in Japan.

Early-stage clinical trials of Ebola and Marburg vaccines are proved safe

  • Posted on: 26 December 2014
  • By: PharmaTutor News

Results of an early-stage clinical trial of two experimental vaccines against Ebola and Marburg viruses—the first to be completed in an African country—showed that they were safe and induced immune responses in healthy Ugandan adult volunteers.

Pages